PANRY BIO

PANRY BIO was founded in March 2022 on the Zhongke Yucheng Incubation Platform, as one of the BioPals ecosystem members. The company leverages the strong R&D capabilities of Tianjin Medical University General Hospital, the Tianjin Institute of Urological Surgery, and the Haihe Laboratory of Synthetic Biology. Focusing on prostate cancer, a highly prevalent tumor among men globally, PANRY BIO is committed to developing next-generation immunotherapy products, including mRNA vaccines, peptide vaccines, and novel gene-editing technology therapies.